Cargando…

The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma—State of the Art and Future Perspectives

SIMPLE SUMMARY: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a specific form of primary liver cancer with features of both hepatocellular and biliary tract cancer. This review provides an overview about the current state-of-the-art diagnostic workup in patients with cHCC-CCA and discusse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eschrich, Johannes, Kobus, Zuzanna, Geisel, Dominik, Halskov, Sebastian, Roßner, Florian, Roderburg, Christoph, Mohr, Raphael, Tacke, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818385/ https://www.ncbi.nlm.nih.gov/pubmed/36612297 http://dx.doi.org/10.3390/cancers15010301

Ejemplares similares

Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art
por: Laschtowitz, Alena, et al.
Publicado: (2023)

Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
por: Auer, Timo Alexander, et al.
Publicado: (2023)

In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?
por: Mohr, Raphael, et al.
Publicado: (2020)

In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma
por: Lurje, Isabella, et al.
Publicado: (2021)

Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update
por: Roßner, Florian, et al.
Publicado: (2023)

Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma
por: Loosen, Sven H., et al.
Publicado: (2020)

Pulmonary Complications in Patients with Liver Cirrhosis
por: Benz, Fabian, et al.
Publicado: (2020)

Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5(th) edition of the World Health Organization classification
por: Auer, Timo A., et al.
Publicado: (2023)

Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review
por: Özdirik, Burcin, et al.
Publicado: (2021)

The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis
por: Lambrecht, Joeri, et al.
Publicado: (2021)

Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
por: Mohr, Raphael, et al.
Publicado: (2021)

From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis
por: Mohr, Raphael, et al.
Publicado: (2021)

Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma
por: Loosen, Sven H., et al.
Publicado: (2016)

Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
por: Roderburg, Christoph, et al.
Publicado: (2020)

The role of the innate immune system in the development and treatment of hepatocellular carcinoma
por: Roderburg, Christoph, et al.
Publicado: (2020)

Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors
por: Geisler, Lukas, et al.
Publicado: (2022)

Prediction of regional lymph node metastasis in intrahepatic cholangiocarcinoma: it’s not all about size
por: Kolck, Johannes, et al.
Publicado: (2023)

Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma
por: Costa, Frederico, et al.
Publicado: (2023)

Mouse models of hepatocarcinogenesis: What can we learn for the prevention of human hepatocellular carcinoma?
por: Vucur, Mihael, et al.
Publicado: (2010)

Pleural Carcinosis of a Cholangiocarcinoma
por: Dziodzio, Tomasz, et al.
Publicado: (2019)

Body composition is associated with disease aetiology and prognosis in patients undergoing resection of intrahepatic cholangiocarcinoma
por: Lurje, Isabella, et al.
Publicado: (2023)

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)
por: Kehmann, Linde, et al.
Publicado: (2023)

Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma
por: Loosen, Sven H., et al.
Publicado: (2019)

Role of the PP2A Pathway in Cholangiocarcinoma: State of the Art and Future Perspectives
por: Cristóbal, Ion, et al.
Publicado: (2022)

Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives
por: Cerrito, Lucia, et al.
Publicado: (2023)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma
por: Roderburg, Christoph, et al.
Publicado: (2021)

Serum CXCL5 Detects Early Hepatocellular Carcinoma and Indicates Tumor Progression
por: Laschtowitz, Alena, et al.
Publicado: (2023)

Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms
por: Kidess, Evelyn, et al.
Publicado: (2023)

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma
por: Renzulli, Matteo, et al.
Publicado: (2021)

CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma
por: Loosen, Sven H., et al.
Publicado: (2017)

Unique Responses of Hepatocellular Carcinoma and Cholangiocarcinoma Cell Lines toward Cantharidin and Norcantharidin
por: Ma, Qixiang, et al.
Publicado: (2018)

Prognostic and Predictive Molecular Markers in Cholangiocarcinoma
por: Pavicevic, Sandra, et al.
Publicado: (2022)

Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)

Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma
por: Alonso-Peña, Marta, et al.
Publicado: (2019)

Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma
por: Murugesan, Karthikeyan, et al.
Publicado: (2021)

Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors
por: Wu, Tianyu, et al.
Publicado: (2021)

Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular‐cholangiocarcinoma after resection
por: Song, Peipei, et al.
Publicado: (2019)

Differential role of chronic liver diseases on the incidence of cancer: a longitudinal analysis among 248,224 outpatients in Germany
por: Loosen, Sven H., et al.
Publicado: (2022)

Outcome of Combined Hepatocellular and Cholangiocarcinoma of the Liver
por: Wang, Jue, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2h3ka6p9t6jr8om5rpc36u1khn